Here are the 10-K annual reports from Biodesix, Inc. (BDSX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BDSX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDSX filings page.
Biodesix, Inc. reports strong 2025 growth as a lung‑focused diagnostics company. The business generated an estimated $88.5 million in total revenue, up 24% from 2024, driven mainly by its Biodesix Lung Diagnostic Testing segment.
Lung Diagnostic Testing produced $79.2 million of revenue from about 62,600 tests, increases of 22% and 15%, while Development Services contributed $9.3 million, up 41%. Gross margin improved to 81% from 78% as the company emphasized operational efficiencies and cost discipline, limiting operating expense growth (excluding direct costs and expenses) to 10% while revenue rose 24%.
Biodesix offers five blood‑based lung tests spanning nodule diagnosis, treatment guidance and monitoring, and estimates over 10 million annual testing opportunities in the U.S. representing a market of more than $27 billion. The company highlights expanding clinical data, growing reimbursement coverage, and multiple ongoing clinical studies, while operating CLIA‑certified, CAP‑accredited laboratories and maintaining an extensive intellectual property portfolio.